2014 & 13 th Annual China Pharmaceutical, Life Science & Healthcare Industry Summit

Loading....

Loading....

Loading....

Loading....

Loading....

Full text

(1)

Joanne Waldstreicher Chief Medical Officer

Worldwide Pharmaceutical Group Johnson & Johnson

Andrew Hodge President China Eli Lilly

Steve Yang, PhD VP, Head of Asia and Emerging Markets iMed AstraZeneca

Eric Zwisler President, China Cardinal Health China

Hear Critical Regulatory Update from Previous & Priority Inviting Keynote Speakers Luke Miels

Regional Head, Asia Pacific Roche

Allan Gabor Managing Director Merck Serono China Xu Haiying

President China Novartis Christian Velmer

SVP, Global Commercial Operations Pfizer

And many more…

Conference

·

Roundtable

·

Summit

Your Best Growth Opportunity in China’s Pharmaceutical Industry in 2014

Join China’s most premier annual event for pharma & life science sectors

Network with over 150 senior officials and pharma CEOs for winning

strategies & cooperation opportunities

Obtain first hand information on the latest drug regulatory changes, new measures of the medical system reform and other policies in the pipeline

Hear exclusive case studies on how to tackle existent and emerging

challenges to continuously grow your business in the local market

Find the best solutions to all your challenges to prosper beyond 2014

Visit us at www.gicsummits.com Media Partners

National Health & Family Planning Commission China Food & Drug Administration

National Development & Reform Commission Ministry of Human Resources & Social Security State Intellectual Property Office

Endorsed by

China International Health Industry Association Shanghai Health Industry Development & Promotion Association

2014 & 13

th

Annual China Pharmaceutical,

Life Science & Healthcare Industry Summit

Addressing the most critical issues facing China’s pharma & life science sector

10

th

& 11

th

April, 2014 | Shanghai China

(2)

Greater China (Mainland China, Hong Kong, Macau & Taiwan) 60% Participant Geographical Breakdown

Participant Industry Breakdown

Other Regions 5%

US & Europe 15%

Asia Pacific 20% Who You Will Meet

Pharma, Life Science, Biopharm & Related 40% Others 5%

Hospitals & Medical Services 20%

R&D, CRO & Clinical Trials 20%

Packaging & Equipments 5%

From the Following Industry Segments

ƒ Pharmaceutical Manufacturing ƒ Pharmaceutical Marketing ƒ Biotech/Biopharmaceuticals ƒ Pharmaceutical Ingredients ƒ Pharmaceutical Distribution ƒ Pharmaceutical Retailing ƒ Medical Affairs ƒ R&D/ Innovation ƒ Clinical Operations

ƒ Channel & Distribution

ƒ Safety & Production

ƒ Solutions & Technical

China’s pharmaceutical market has continued to experience pronounced and rapid expansion in recent years growing at 20% at average, nearly doubling every four years.

Yet behind this picture of dynamic sales growth, hurdles remain for China’s pharmaceuticals businesses. Industry consolidation, access to insurance, changing demographics and emerging issues brought by the new medical system reform will all alter the playing field in the next few years

This is your best opportunity of the year to meet key officials and industry leaders to obtain first hand information on all the recent regulatory changes, new medical system reform, future industry trends and successful

strategies for continuous growth and profitability in China. Do Not Miss It!!

Why Sponsor/Participate in 2014 & 13th Annual China Pharma, Life Science & Healthcare Industry Summit Week (CPHIS 2014)?

ƒ Because CPHIS is China’s most important industry event for updating latest regulatory development and winning strategies in China’s booming yet challenging pharma & healthcare market

ƒ Because over 150 senior officials & CEOs gather at CPHIS every year to discuss pertinent issues, exchange new ideas, and explore opportunities for co-operations

ƒ Because CPHIS is your best opportunity and the most powerful marketing platform to target decision makers from all the stakeholders in pharmaceutical and healthcare sectors in China Past Event Highlights

C

C

C

a

a

a

p

p

p

i

i

i

t

t

t

a

a

a

l

l

l

i

i

i

s

s

s

i

i

i

n

n

n

g

g

g

o

o

o

n

n

n

E

E

E

m

m

m

e

e

e

r

r

r

g

g

g

i

i

i

n

n

n

g

g

g

O

O

O

p

p

p

p

p

p

o

o

o

r

r

r

t

t

t

u

u

u

n

n

n

i

i

i

t

t

t

i

i

i

e

e

e

s

s

s

i

i

i

n

n

n

C

C

C

h

h

h

i

i

i

n

n

n

a

a

a

s

s

s

P

P

P

h

h

h

a

a

a

r

r

r

m

m

m

a

a

a

c

c

c

e

e

e

u

u

u

t

t

t

i

i

i

c

c

c

a

a

a

l

l

l

&

&

&

L

L

L

i

i

i

f

f

f

e

e

e

S

S

S

c

c

c

i

i

i

e

e

e

n

n

n

c

c

c

e

e

e

I

I

I

n

n

n

d

d

d

u

u

u

s

s

s

t

t

t

r

r

r

y

y

y

Marketing, Retailing & Distribution 10%

CEOs, Managing Directors, VPs, General Managers, Senior Directors & Heads of

ƒ China Strategies & Operations

ƒ Strategic Planning/M&A

ƒ Government/Regulatory Affairs

ƒ Drug Bidding & Access

ƒ Sales & Marketing

ƒ Product Line Management

ƒ Clinical Research

ƒ Hospitals & Clinics

ƒ Medical Equipment

ƒ Solution Providers

ƒ Legal & Consultancy

ƒ Market Research

13

th

CPHIS

(3)

Thursday 10

th

April, 2014

08.30 Registration & Morning Tea 08.50 Opening Address from the Chairman

OPENING REMARK

09.00 China’s Healthcare Landscape and In-Depth Analysis of the Pharmaceutical Industry for the Next Ten Years

ƒ What are we to expect in and beyond 2014 for the healthcare, pharmaceutical and life science sector

ƒ What impacts will the latest medical system reform, drug administration measures including the GSK incident have on future business operations and practices of the industry

ƒ Patented vs. generic medicines, retail pharmacies vs. hospital sales: how the healthcare market and pharma business model will evolve in next 5 years

ƒ What opportunities/challenges is the rapidly diversifying business environment creating for different players: multinational vs. local

ƒ Analysing growth potentials by key product types and segments

ƒ Where will new opportunities lie, what are the high margin business trends for the next decade REGULATORY ADDRESS

09.30 Latest Development of the Healthcare System Reform and Public Hospital Reform: New Initiatives, Legislations and Implementation Measures

ƒ Latest development and initiatives of China’s medical system reform

ƒ Focus of new rural cooperative medical service

ƒ Direction of public hospital reform and incentives for private investment in medical service sector

ƒ What legislation can be expected in the coming years and industry implications

National Health and Family Planning Commission

10.00 Updating on the Essential Drug List and Future Directions of Healthcare Insurance and Payment System Reform

National Health & Family Planning Commission Ministry of Human Resources & Social Security

10.30 Morning Refreshment & Network Break KEYNOTE PANEL

10.45 Exploring New Growth Models for Big Pharma in China: How to Enable Innovation and Drive Growth in China in an Environment of Intensifying Supervision and Cost Pressure

ƒ What new business habits will emerge and how pharma business models will adapt under the new healthcare reform and stricter industry supervision

ƒ Winning strategies in an era of cost containment

ƒ New collaboration models: managing China innovation for the future

ƒ Growing beyond major cities - which internal cities offer the best prospect of long-term growth

ƒ China strategy in a regional/global context 11.30 Implementing Compliance Best Practices as a

Winning Differentiator in Today's Complex and Competitive Business Landscape

ƒ Current industry and regulatory overview

ƒ Patient, HCP and Distributor’s perspectives on compliance and ethics

ƒ What’s needed to improve compliance today

ƒ Best practices in medical affairs and clinical trial compliance

ƒ Compliance issues in social media and digital marketing

ƒ Negotiating, auditing and monitoring third party relationships

12.00 Networking Lunch

KEYNOTE SESSIONS

12.45 How to Capitalise on the Potential of Personalised Medicine

ƒ What are the challenges and barriers for personalised medicine

ƒ How can they be addressed to ensure the potential of personalised medicine becomes a reality in improving the health outcomes of patients

ƒ How to make personalized medicine a commercial success for life science companies

13.15 Accelerating Innovation and Collaboration across Clinical R&D and Healthcare

ƒ Changing notion of innovation

ƒ Managing challenges of translating early stage science into novel pharmaceutical products

ƒ R&D opportunities and strategies tailored to the huge unmet medical needs in the local market 13.45 Managing Business Development and Financing

Challenges In China Today: An Analysis Of Top Deal Structures

14.15 Afternoon Refreshment & Networking Break 14.30 Regulatory Insight: Strategies to Accelerate Time to

Market

ƒ Understanding the CFDA “Green Channel” and parallel approval/review system for new drug applications and ethical committee evaluations

ƒ Exploring effective strategies/approaches to accelerate development timeline and launch products more rapidly in China

15.00 China’s CMC Regulations and Corporate Response 15.30 Drug Patent Application & IPR Protection in China:

New Developments and Requirements

16.00 Regulatory Changes on Preclinical/Clinical Safety Supervision, ADR Monitoring and Post-Market Surveillance

ƒ New development of the drug safety monitoring system and post-market evaluation in China

ƒ Pharmacovigilance issues and best practice

ƒ Managing drug safety issues in manufacturing, packaging and transportation

ƒ Measures to enhance drug safety compliance China Food & Drug Administration

TECHNOLOGY SHOWCASE

16.30 The Future of Pharmaceutical Manufacturing

ƒ Pharma manufacturing landscape

ƒ Initiatives to reduce tech transfer costs, and improve location and operational flexibility

ƒ Capitalizing on continuous manufacturing

ƒ Establishing a quality agreement with a unified approach for all suppliers

ƒ Assessing internal quality system effectiveness 17.00 Managing Pharmaceutical Supply Chain and Cold

Chain in China

ƒ Latest GSP updates and policies on application and registration of importing clinical trial control drugs

ƒ How to improve your demand planning strategies in order to dramatically reduce costs

ƒ Professional 3PL service platform for pharmaceutical manufacturers

ƒ Ensuring quality of temperature-controlled products during transportation to county-level destinations or under extreme weather conditions

ƒ Leveraging win -win partnerships with 3PL/4PL operators and other pharma companies to ensure a cost-effective and operationally-sound logistics 17.30 Closing Remarks from the Chair and Close of Day

(4)

Friday 11

th

April, 2014

08.30 Registration & Morning Tea 08.50 Opening Address from the Chairman

REGULATORY UPDATE

09.00 Updating on Drug Registration, GXP

Administration & Key Enforcement Measures in the Pipeline

ƒ Latest development and regulatory changes on drug administration

ƒ New initiatives in clinical trial, new drug registration, drug approval and appraisal system in China

ƒ The new GMP standard and changes in other GXP supervision measures

ƒ Improvement and enforcement of national drug standards and electronic monitoring

ƒ Other policies and measures in the pipeline China Food & Drug Administration

09.30 Key Focus of Drug Pricing Administration in 2014 National Development & Reform Commission

KEYNOTE ADDRESS

10.00 Optimising Pricing and Access Strategies in an Age of Austerity

ƒ Overview of current issues and trends in global market access and pricing

ƒ How to get the right drug to the right patient at the right price

ƒ The evolving landscape and impact on pricing and reimbursement levels in China

ƒ Mitigating the effect of cost constraints on rare diseases treatment

10.30 Morning Refreshment & Network Break 10.45 China Hospital Market Potential Estimate,

Physician Access and New SFE Strategies

ƒ How will the sales model evolve in the changing business environment

ƒ Beyond hospital targeting and segmentation: modelling and forecasting

ƒ Sales force optimisation: Balance over-expanding vs. missed opportunity, broad vs. focus

ƒ Building a robust sales force while keeping it flexible to allow for changes in local environment

11.15 Hospital Drug Tendering: Future Policy Directions and Industry Implications

11.45 Managing Pharmacy/Hospital Channels & Drug Distribution in a Stricter Regulatory and Operation Environment

12.15 Tapping into China’s “Broader” Market

ƒ Analysing China's community healthcare market and its potential opportunities

ƒ Specific strategies and their potential utility by domestic players vs. global pharma

ƒ Proven tactics employed by international companies who've made the effort to "go west"

12.45 Networking Lunch

13.30 How to Leverage the Power of CI to Drive Value and Maximize Assets Before Patent Expiration

ƒ The impact of a changing pharma landscape on the competitive intelligence function

ƒ Leveraging the power of CI in market access

ƒ Turning market research/business intelligence to insights to strategy

ƒ KOL mapping and profiling

ƒ Applying big data approaches to competitive intelligence challenges

14.00 Determining and Managing Your Localization Strategies

ƒ Key considerations when supplying the rapidly growing Chinese market: import products vs. local product manufacture

ƒ Managing localization of manufacturing of imported drugs that are covered by a compound patent

ƒ Localization of late-stage pipeline pharmaceuticals products

14.30 Afternoon Refreshment & Networking Break KEY SEGMENT OUTLOOK & STRATEGIES 14.45 Investing in the Biopharma Sector: High Growth

Opportunities, Emerging Challenges and Successful Business Models in China

ƒ The biopharma industry in China: Evolving business models, industry expansion vs. capital expansion, and IP right protection issues

ƒ Impact from bioinformatics, drug licensing and alliance management in China

ƒ Latest biopharma technologies, innovations on protein & gene pharmaceuticals and

intermediates

ƒ Strategies for moving early stage biotech to the growth phase of the life cycle

ƒ Future outlook and investment/exit strategies 15.30 Generics Market Strategies

ƒ Outlook of China’s generic medicines market and the impact of its changing regulations

ƒ Market access and penetration strategies

ƒ Capturing the niche market: Effective business models and niche product portfolio for flourishing and winning in the generic war

ƒ Debating on the incentives to innovate vs. challenges of affordability

PANEL DISCUSSION

16.15 Structuring a Profitable China Operation

ƒ How will China development in the global pharmaceuticals industry

ƒ Patented and generic drugs: their role in the future of the market

ƒ Regulatory changes and health system reform

ƒ Strategic options for future growth 17.00 Closing Remarks from the Chair and End of

Summit

(5)

Reserve Your Seats Today

Tel: +86 21 5186 0870 Fax: +86 21 6132 7559 davidl@gicsummits.com

Custom-tailored Marketing Solutions

Trade shows are out. Mass marketing is out. Traditional advertising is out. There's a huge shift toward targeted, segmented marketing and THAT is exactly what CPHIS provides. If you want access to the top professionals in China’s pharmaceutical, life science & healthcare industry, invest in CPHIS 2014, we can create custom packages for budgets of any size. We promise to deliver results you can measure.

As a business to business professional, you recognize how challenging it is to navigate through to the actual decision-makers. Our delicately-designed events attract attendance by top level professionals across industries and functions. CPHIS prides itself on delivering content of the highest quality, focusing on business strategy, market share and brand performance.

We guarantee:

ƒ Custom designed packages to match your budget and marketing objectives

ƒ Face-to-face interaction and networking with top decision makers in a low pressure environment

ƒ Opportunities to demonstrate your expertise through non-commercial presentations

ƒ Extensive brand exposure through promotion of your company within an extensive integrated marketing campaign

ƒ Positioning above your competition

ƒ Strategically designed exhibit areas for optimum traffic

ƒ Access to post-conference feedback

Our attendees seek your products and services. Together we can provide them with a one-stop-shop for all their marketing and business needs.

Return on Investment

ƒ Strategic exposure and branding driven events with access to hundreds of qualified decision makers

ƒ Effective platform to position products to key decision makers from a target audience in a short period of time

ƒ Opportunity for face-to-face contact with key buyers at a competitive cost per contact and timely manner

ƒ Ability to access numerous contacts in an environment conducive to conduct business

CPHIS 2014 offers solution providers a variety of ways to meet their sales, marketing and business development objectives and to achieve their corporate targets. By concentrating an exhibition, conference and product demonstrations in one place, buyers from the entire region will use this opportunity to improve their awareness of the latest products, services, techniques and trends in their specific sector. CPHIS 2014 will assist all attendees in meeting the current and future challenges in the pharma, life science & healthcare industry.

Selected Participants at Past CPHIS

Abbott Laboratories Actavis Alcon China Allergan AstraZeneca Aventis Bayer Healthcare Baxter Beufour Ipsen Boehringer Ingelheim Bristol-Myers Squibb Bu Chang Group Dr. Reddy’s DSM Eli Lilly Fosun Group NovoNordisk Pfizer Ranbaxy Rhodia Roche SASS SSPC Schering AG Schering Plough SK Solvay Takeda Tasly Group Teva Tianjin SK&F Wan Bang GlaxoSmithKline Hutchison Healthcare Johnson & Johnson Livzon Pharma LG Life Science Merck AG

Merck Sharp & Dohme Novartis

Wyeth Xi’an Janssen Xiu Zheng Pharm Yangzijiang Group Yamanouchi Yuan Da Group ZLB Behring Zuellig Pharma

13

th

CPHIS

(6)

Please return this form to David Liu

Fax No: 0086 21 6132 7559

Email address: davidl@gicsummits.com

DATE

: 10

th

& 11

th

April, 2014 (Main Conference)

2014

4

10 - 11

(

主会议

)

VENUE

: Shanghai, China

中国

上海

ORGANISER: Global Intelligence Communications

REGISTRATION FORM

登记合同

Name/

姓名

: _________________________ Position/

职位

: _________________________ Email/

电子信箱

: _________________________

Name/

姓名

: _________________________ Position/

职位

: _________________________ Email/

电子信箱

: _________________________

Name/

姓名

: _________________________ Position/

职位

: _________________________ Email/

电子信箱

: ________________________

Organisation/

机构

: __________________________________ Address/

地址

: _________________________________________________

Postcode/

邮编

: _____________________________________ Tel/

电话

: ____________________ Fax/

传真

: ________________________

Authorisation 授权

Name/

姓名

: _________________________ Position/

职位

: _________________________ Date/

日期

: _____________________________

Signature/

签名

: _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ (This booking is invalid without a signature

本定单签名有效

)

______________________________________________________________________________________________________________

Registration & Level of Participation 参会确认及参会形式

‰ Sponsorship: Participate as a sponsor to enjoy tailored marketing exposure & business development opportunities from the event.

赞助:作为铂金、黄金或展览赞助商参与本次峰会,获得针对您目标市场 的最大宣传、展览、演讲以及客户拓展机会

‰ Delegate: US$ 2,098/RMB 12,800/ Person (Fee is inclusive of a set of conference documentation, refreshments, lunch & access to all event activities).

参会:每人2,098 美元/人民币12,800元 (包括资料、茶点、午宴及参与两 天全部活动)

‰ Membership: US$3,595/RMB 22,000/Person for attending this event free of charge plus one year admission to all GIC pharma related events

成为VIP会员:每人每年3,595美元/人民币22,000元:免费参加此次活 动,并可参加一年内所有GIC医药行业会议及活动

‰ Documentation: If you are unable to attend the conference but wish to receive the conference documentation (US$ 650/RMB 4,000/ Set including postage and packing)

资料:如无法参会但希望得到会议资料,请填写销售合同,在本方框上打 钩并回传 (每套650美元/人民币4,000元,包括邮费和包裹费)

Payment Method 付款方式

Confirmation of Registration 确认方法

Confirmation Letter/ 确认函

All paid registration will be confirmed in writing upon clearance of payment. Please contact us if you did not receive our confirmation one week from your fax out.

如您发出登记合同一周后仍未收到相关确认函,请致电我们

Formal invoice/ 正式发票

After receiving the payment, a formal receipt will be issued to the client. 在收到您的会务费后,将寄出正式发票。

Cancellations 取消

By returning this completed form, the client hereby agrees that GIC will not be able to mitigate its losses for any less than 50% of the total contract value. Cancellation must be received 4 weeks before the event. Delegate substitutions are welcome at any time.

此填好的登记表回传GIC公司后立即生效。会前4星期内任何取消 客户承担总合同费用50%。您可以在会前任何时候替换参会人员。 Indemnity: Should for any reason outside the control of GIC, the venue or speakers change, or the event be cancelled due to an act of terrorism, extreme weather conditions or industrial action, GIC shall endeavour to reschedule, but the client hereby indemnifies and holds GIC harmless from and against any and all costs, damages and expenses, including attorneys’ fees, which are incurred by the client.

‰ I’m paying by T/T transfer/ bank transfer/ 我通过电汇/银行转账付款

Pay to: The Industry and Commercial Bank of Shanghai, China Beneficiary: Global Intelligence Communications China Co., Ltd Account No.: 1001235919016970816

SWIFT Code: ICBKCNBJSHI

请在回传此报名表格后五个工作日内付款至: 帐户名称: 上海维锡商务咨询有限公司

开户行: 中国工商银行上海市分行南京东路支行 人民币帐号: 1001235919016970816

开户行代码: 102290023598

‰ Please debit my credit card (non-domestic)/ 请借记信用卡 (非境内卡)* * ‰ Visa/ 威士卡‰ Mastercard/ 万事达卡‰ American Express/ 美国运通卡

Card Holder’s Name/ 持卡人姓名: ________________________________ Card Number/卡号:

‰‰‰‰‰‰‰‰‰‰‰‰‰‰‰‰

Signature/签名: _ _ _ _ _ _ _ _ _ _ _ Expiry Date/有效期: ______/______ * Additional information required to complete the payment via credit card 必须提供额外信息完成信用卡付款,我们将与您联系。

13

th

CPHIS

Shanghai China

2014 & 13

th

Annual China Pharma, Life Science & Healthcare Industry Summit

Figure

Updating...

References

Updating...

Related subjects :